ALZN vs. XCUR, SEEL, KA, OGEN, SONN, CPHI, GTBP, SNPX, DRUG, and SNGX
Should you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Exicure (XCUR), Seelos Therapeutics (SEEL), Kineta (KA), Oragenics (OGEN), Sonnet BioTherapeutics (SONN), China Pharma (CPHI), GT Biopharma (GTBP), Synaptogenix (SNPX), Bright Minds Biosciences (DRUG), and Soligenix (SNGX). These companies are all part of the "pharmaceutical preparations" industry.
Alzamend Neuro (NASDAQ:ALZN) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, community ranking, dividends, profitability, earnings, valuation and media sentiment.
Alzamend Neuro has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Exicure has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 10.9% of Alzamend Neuro shares are owned by company insiders. Comparatively, 3.9% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Alzamend Neuro had 1 more articles in the media than Exicure. MarketBeat recorded 4 mentions for Alzamend Neuro and 3 mentions for Exicure. Alzamend Neuro's average media sentiment score of 0.50 beat Exicure's score of 0.24 indicating that Alzamend Neuro is being referred to more favorably in the media.
Exicure has higher revenue and earnings than Alzamend Neuro. Alzamend Neuro is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.
Exicure's return on equity of 0.00% beat Alzamend Neuro's return on equity.
Exicure received 5 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 47.37% of users gave Exicure an outperform vote.
Summary
Exicure beats Alzamend Neuro on 8 of the 13 factors compared between the two stocks.
Get Alzamend Neuro News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alzamend Neuro Competitors List
Related Companies and Tools
